SAN DIEGO, Oct. 21, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
diagnostic tests and services, announces the appointment of
Samuel D. Riccitelli to its Board of
Directors, effective immediately. Mr. Riccitelli is joining
the Board ahead of the planned retirement of Bruce A. Huebner, who will retire from the
Biocept Board of Directors on November 30,
2020.
Mr. Riccitelli brings to Biocept extensive experience in the
molecular diagnostics industry, having served in executive-level
positions and on the Boards of multiple publicly traded
companies. At Biocept, he will initially serve on the Audit
Committee and the Science and Technology Committee.
"Sam's proven success with high-growth diagnostics companies,
strong knowledge of the public equity markets and extensive
corporate governance experience make him a welcome addition to our
Board. We expect Sam will make significant contributions
toward achieving our strategic growth initiatives and opening new
opportunities as we build upon our position as a leader in
molecular diagnostics and continue to rapidly grow," said Biocept
Chairman David F. Hale. "We
very much appreciate the many contributions Bruce has made as a
valued member of our Board for the past seven years, consistently
bringing to Biocept keen insights in diagnostics sales, marketing
and reimbursement. We wish him well in his retirement."
"This is an exciting time to join the Biocept Board as liquid
biopsy moves toward the goal of becoming standard of care and the
company is experiencing rapid growth with its infectious disease
offering," said Mr. Riccitelli. "I see a substantial
opportunity for Biocept and its proprietary Target Selector™
technology to play an ever-increasing role in improving clinical
outcomes for patients. I look forward to working with the
team in advancing Biocept's programs and delivering value to
stockholders."
Mr. Riccitelli has been in the healthcare industry for more than
35 years. He currently serves as an independent consultant to
healthcare companies and is a Director of OrthoPediatrics Corp.
(Nasdaq: KIDS), a company focused on the orthopedic implant needs
of children. He previously was Chief Executive Officer of
Pathnostics, LLC, a molecular diagnostics company focused on
improving antibiotic stewardship. Prior to that, he served as
Chairman of Precipio, Inc., a publicly traded diagnostic services
company, as President, Chief Executive Officer and Director of
Signal Genetics, Inc., a publicly traded molecular diagnostic
company acquired by miRagen Therapeutics, Inc., and as Executive
Vice President and Chief Operating Officer of Genoptix, Inc., a
publicly traded diagnostic company acquired by Novartis.
Earlier in his career, Mr. Riccitelli held a number of
R&D and general management positions at Becton, Dickinson and Company, and served as Vice
President, General Manager and Director for BD Ventures, LLC, a
venture capital fund. Mr. Riccitelli received a B.A. from
Washington and Jefferson College and an
M.S. in Engineering from The University of
Texas.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. In
addition, Biocept conducts COVID-19 testing to support efforts to
fight the pandemic. For additional information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding the ability of certain individuals to make
significant contributions toward achieving our strategic growth
initiatives and opening new opportunities for Biocept, liquid
biopsy's ability to become standard of care, the potential for our
proprietary Target Selector™ technology to play an ever-increasing
role in improving clinical outcomes for patients, delivering value
to stockholders, the ability of our tests to provide clinically
actionable information, and the ability of Biocept's platform to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options, such statements
are forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-appoints-samuel-d-riccitelli-to-its-board-of-directors-301156701.html
SOURCE Biocept, Inc.